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Abstract
Background: Although pacemakers are primarily used for the treatment of bradycardia,
diagnostic data available in current pacemakers allow them to be also used as sophisticated,
continuous monitoring devices. Easy access to these stored data may assist clinicians in making
diagnostic and therapeutic decisions sooner, thus avoiding potential long-term sequelae due to
untreated clinical disorders. Internet-based remote device interrogation systems provide clinicians
with frequent and complete access to stored data in pacemakers. In addition to monitoring device
function, remote monitors may be a helpful tool in assisting physicians in the management of
common arrhythmia disorders.
Methods: The Pacemaker REmote Follow-up Evaluation and Review (PREFER) trial is a
prospective, randomized, parallel, unblinded, multicenter, open label clinical trial to determine the
utility of remote pacemaker interrogation in the earlier diagnosis of clinically actionable events
compared to the existing practice of transtelephonic monitoring. There have been 980 patients
enrolled and randomized to receive pacemaker follow up with either remote interrogation using
the Medtronic CareLink® Network (CareLink) versus the conventional method of transtelephonic
monitoring (TTM) in addition to periodic in-person interrogation and programming evaluations.
The purpose of this manuscript is to describe the design of the PREFER trial. The results, to be
presented separately, will characterize the number of clinically actionable events as a result of
pacemaker follow-up using remote interrogation instead of TTM.
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Pacemaker therapy is indicated to treat bradycardia due to
sinus node or atrioventricular conduction disorders. In
addition to pacing, current devices have expanded record-
ing and diagnostic capabilities, providing continuous car-
diac monitoring and long-term trended clinical
information. Pacemakers can store atrial as well as ven-
tricular high rate episodes, along with percentage of atrial
and ventricular pacing, capture management data, and
many other clinically useful parameters. Furthermore, the
atrial high rate diagnostic data in pacemakers have been
shown to have good sensitivity and specificity for the diag-
nosis of atrial fibrillation (AF) [1,2]. Pacemaker therapy
monitoring is most frequently achieved in the United
States with a combination of in-person programming
evaluations and transtelephonic monitoring (TTM). TTMs
are primarily used to monitor battery status, and are per-
formed at a frequency adjusted as implant duration
progresses. TTMs, however, have no ability to download
the monitored data stored in pacemakers. Full device data
interrogations are only available through in-person pro-
gramming evaluations.
The advent of internet-based remote monitoring systems
allow for full device interrogation while the patient is in
their home or other remote location. This allows clini-
cians to have more frequent and complete access to the
device data without creating a substantial burden on the
patient and the clinician with increased office visits. In
addition to the Medtronic CareLink® Network (CareLink)
(Minneapolis, MN, USA), remote monitoring systems are
also available through Biotronik Home Monitoring (Ber-
lin, Germany), St. Jude Housecall™ (St. Paul, MN, USA),
and Boston Scientific Latitude® (St. Paul, MN, USA). The
functionality of these systems has been well described for
use in patients with implantable cardioverter-defibrilla-
tors (ICD). Clinically significant findings such as ventricu-
lar tachycardia [3], silent AF [4], early volume overload
[5], and lead fractures causing inappropriate shocks [6]
have been detected during clinicians' reviews of the
remote transmissions. Remote monitoring systems, how-
ever, have not been described for use in patients with
pacemakers.
The purpose of the PREFER trial is to evaluate the utility of
systematic remote interrogation to monitor pacemaker
and patient condition in order to increase the awareness
of physicians to any events which may necessitate early
clinical intervention.
Methods/Design
Hypothesis
The PREFER trial examines the hypothesis that quarterly
device monitoring by remote interrogation will result in
the earlier diagnosis of clinically actionable events com-
pared to the combination of TTM and routine office visits.
Primary endpoint
The primary endpoint is the rate of first diagnosis of clin-
ically actionable events in patients whose pacemakers are
followed by remote interrogation versus those whose
pacemakers are followed by office visits augmented by
TTM. The goal of early identification of clinically actiona-
ble events is to have early intervention by a clinician,
which could impact the clinical sequelae. The clinically
actionable events were selected on the basis that their
presence merits a clinical decision or further medical
assessment. Clinically actionable events are defined as:
• Atrial tachycardia (AT)/AF episodes ≥ 48 hours (defined
as two consecutive days in which the device records at
least 18 hours of AT/AF per day)
• Ventricular pacing that has increased by 30 percent rela-
tive since last device interrogation
• Sensed ventricular rate of ≥ 100 bpm during atrial
arrhythmia for at least 20 percent of the time since previ-
ous device interrogation
• Non-sustained ventricular tachycardia (NSVT) ≥ 5 beats
• New onset AT/AF in patients with no prior history of AT/
AF
• Loss of capture
• Increase in pacing voltage threshold ≥ 1 V
• Significant changes in atrial or ventricular lead imped-
ance, defined as:
 < 200 of > 2000 ohms
 Unstable lead impedance deemed to be clinically action-
able
 ≥ 50 percent change in lead impedance since last interro-
gation
• Elective Replacement Indicator (ERI) or End of Life
(EOL)
Secondary endpoints
The first secondary endpoint of the trial is to characterize
the frequency of actions for each of the clinically actiona-
ble events defined above. There are nine additional sec-
ondary objectives; each assesses the contribution ofPage 2 of 6
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objective.
Design
The PREFER trial is a prospective, randomized, parallel,
unblinded, multicenter, open label clinical trial to investi-
gate the clinical value of remote interrogation in the man-
agement of patients with pacemakers. All study patients
received a Medtronic Kappa® 900, EnPulse®, Adapta™, or
Versa™ device supported by CareLink. The pacemakers are
either single- or dual-chamber devices. Fifty investigative
centers in the United States (US) enrolled a total of 980
patients between May 2004 and March 2007, with
planned 12-month follow up.
The primary inclusion criteria are:
 Patient is at least 30 days post system modification,
including new device implant, device upgrade, or lead
changes.
 Patient has access to an analog phone line.
 Patient is capable of operating the TTM monitor and the
CareLink Monitor.
The exclusion criteria are:
 Enrollment in another pacemaker clinical study that
might confound the results of this trial.
 Patient is a candidate for an ICD.
All patients who met eligibility requirements and signed
an Institutional Review Board (IRB) approved PREFER
trial Informed Consent Form and an Authorization for the
Use and Disclosure of Health Information underwent an
in-office baseline evaluation to quantify baseline charac-
teristics. Baseline evaluations included pacemaker infor-
mation, cardiovascular medical and surgical history, New
York Heart Association (NYHA) classification, and
arrhythmia history.
Randomization
Patients were randomized 2:1 to remote interrogation at
three month intervals or TTM evaluations at two month
intervals. A permutated block randomization was used to
randomize the subjects. Patients who were randomized to
follow up with the remote interrogation will transmit
pacemaker information at 3, 6, and 9 months after enroll-
ment and have an office visit at 12 months post-enroll-
ment. The TTM control subjects with single chamber
devices will transmit 30 second TTM strips with and with-
out magnet application at 2, 4, 6, 8, and 10 months after
enrollment and have an office visit at 12 months. Patients
with dual chamber devices will transmit via TTM at 2, 4,
8, and 10 months after enrollment, with office visits at 6
and 12 months post enrollment. The frequency of TTM
transmissions is the maximal permitted under Centers for
Medicare and Medicaid Services (CMS) reimbursement
guidelines [7] and reflective of average frequency of TTM
transmissions from Medicare patients. The trial design
flowchart is shown in Figure 1.
Programming requirements
The objective of the programming requirements for the
PREFER trial is to detect AF (as inferred by atrial high rate
episodes), and/or ventricular high rates for either AF with
rapid ventricular response rate or ventricular tachycardia.
Specific requirements are listed in Table 1.
Data collection
All scheduled and unscheduled transmissions will be
recorded. Designated physicians and nurses at the clinical
site will determine if a clinically actionable event can be
diagnosed based on the transmitted data. Additional
information will be collected at each office visit, including
medication changes and the performance of device inter-
rogations. The data collected and stored during interroga-
tions consists of an evaluation of thresholds, lead
impedance, battery voltage, as well as a review of device
diagnostics, and stored electrograms.
Trial design flowchartFigure 1
Trial design flowchart. Trial design.
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Sample size methods and assumptions
Data from the Atrial High Rate (A-HIRATE) study were
used to estimate the survival rates for patients in each arm
of the PREFER trial. The A-HIRATE study evaluated pace-
maker patients implanted with a Kappa 700 or Kappa 900
device [8]. Due to device diagnostic limitations of the
Kappa 700, only the 157 subjects in the A-HIRATE study
that were implanted with a Kappa 900 device and fol-
lowed through at least one month post-implant were used
for event rate estimation, as this most closely approxi-
mates patients in the PREFER trial.
Simulations were used to determine the sample size nec-
essary to evaluate the primary objective while following
patients through quarterly remote interrogations com-
pared to the combination of TTM transmissions and in-
office visits, while achieving 80 percent power and α =
0.05. A sample size requirement of 700 subjects was deter-
mined.
Analysis of primary objective
The time to first diagnosis of a clinically actionable event
or censoring will be determined for each randomized sub-
ject. The Peto & Peto modification of the Gehan-Wilcoxon
test will be performed [9]. Only events diagnosed by the
clinician will count toward the primary endpoint. If the
test yields a p-value less than 0.05, it will be concluded
that the freedom from first diagnosis of clinically actiona-
ble event(s) is significantly lower when patients are fol-
lowed through remote interrogation as they were in this
trial, compared to being followed through TTM and
scheduled in-office visits.
Analysis of secondary objectives
The same analysis will be repeated for each of the individ-
ual events that make up the composite primary endpoint.
In addition, actions taken in response to the clinician
awareness of these events will be summarized.
Supplemental analyses
Subsequent to verification of database accuracy and clo-
sure, an examination of the distribution of each study
endpoint will be performed. Descriptive statistics for each
demographic variable will be calculated which include
measures of average, variability, frequency, and a count of
the number of missing values. No data imputation will be
performed. When the mean is found not to be an appro-
priate measure of central tendency, alternative statistics
will be considered (e.g. median).
The distribution of demographic and clinical background
parameters will be summarized for the study population
overall and for each relevant study group.
Subjects in the remote interrogation arm of the trial will
be asked to complete a patient survey at the 12 month
visit in order to characterize the burden of in-office fol-
low-up assumed by patients and their family. The survey
questions include mileage traveled and time spent by the
patient to reach the office, type of transportation used,
necessity of the patient to take time off of work for the
office appointment, and time spent by any family mem-
bers in order to bring patient to the office. Descriptive sta-
tistics will be computed to summarize the results of the
questionnaire.
Discussion
The PREFER trial hypothesized that the systematic remote
interrogation allows clinicians earlier and more complete
access to pacemaker diagnostic data than TTM and sched-
uled in-office visits. If the results support this hypothesis,
events such as ventricular response rate in AF, presence of
NSVT, rising lead thresholds, and significant changes in
lead integrity and battery status, will therefore be detected
earlier so that earlier clinical actions and decisions may
then take place. Thus, the pacemaker monitoring system
can become much more a part of clinical decision and
management.
One of the most common arrhythmias encountered in
pacemaker patients is AF. In a study by Gillis et al of inci-
dence of AF in pacemaker patients, 15 percent of patients
who developed AF as documented on their pacemakers
did not have AF pre-implant [10]. In the A-HIRATE trial,
46 percent of patients without a history of AF developed
at least one atrial high rate episode (AHRE) by 24 months
[8]. Because symptoms are often inaccurate [11] and
patients are frequently asymptomatic in AF, earlier identi-
fication of AF by pacemakers, with frequent access to the
data via remote monitors, can mean earlier initiation of
appropriate anticoagulation which may reduce stroke
events.
The relationship of AF burden to stroke risks remains
unclear. In an ancillary study from the MOde Selection
Trial (MOST), patients with atrial high rate episodes
(AHRE) greater than 5 minutes had twice the death and
stroke rates as patients without any AHRE [2]. In another
study, patients with AHRE greater than 1 day had a 3-fold
increase in strokes compared with patients with AHRE less
than a day [12]. The continuous monitoring capabilities
Table 1: Programming requirements
Parameter Value
Atrial high rate episode Rolling
Ventricular high rate episode Rolling
Ventricular minimum detection duration rate 5 beatsPage 4 of 6
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ciation between the amount of AF burden and stroke
rates. The TRENDS study, which aimed to study the rela-
tionship between duration of AHRE and stroke events in
patients with AF and who are not anticoagulated, has
completed enrollment and is currently in analysis phase,
and will be providing more data [13]. The ASSERT study
is also underway and will evaluate whether the detection
of AHRE with pacemaker telemetry predicts an increased
risk of stroke and other vascular events [14]. If a relation-
ship does exist between the duration of AF and stroke
risks, then the ability to diagnose AF as soon as possible
via a remote monitoring system could indeed be a clini-
cally valuable tool.
Other advantages of remote monitoring of pacemakers
include the ability to access rate histograms. In patients
with known AF, rate control is crucial to avoid tachycar-
dia-mediated cardiomyopathy, and frequent remote
access to rate histograms can allow clinicians to better
monitor the success of rate control. Additionally, the
potential detrimental effects of right ventricular pacing
have gained prominence in recent years. A substudy from
MOST demonstrated an increased risk of heart failure hos-
pitalization in patients who had over 40 percent ventricu-
lar pacing [15]. The incidence of AF also increased with
right ventricular (RV) pacing. Pacemakers now document
the percentage of RV pacing delivered, thus allowing clini-
cians to make programming changes to limit the amount
of RV pacing. Ventricular high rate episodes recorded by
pacemaker may also suggest NSVT, which may be an indi-
cation of cardiomyopathy in patients not previously sus-
pected to have structural heart disease. Appropriate
screening can then be performed to assess the patients'
risks for sudden cardiac death and candidacy for upgrade
to an ICD.
Remote monitoring systems are in widespread use for
monitoring ICDs, but have not yet been studied for the
monitoring of pacemakers. To our knowledge, this is the
first large, multi-centered trial to compare the utility of
remote monitoring systems with the existing system of
TTM and office visits. It is our hypothesis that pacemaker
patients can develop clinically significant arrhythmic
issues, that pacemaker diagnostic data are sophisticated
and numerous, and that frequent access to these data via
remote monitoring can result in earlier actions by clini-
cians.
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